Cargando…

Metabolic Dysfunction and Asthma: Current Perspectives

The increasing knowledge of the mechanisms involved in metabolism is shifting the paradigms by which the pathophysiology of many pulmonary diseases is understood. Metabolic dysfunction is recognized in obesity-associated asthma, but other metabolic conditions have been shown to be independently rela...

Descripción completa

Detalles Bibliográficos
Autores principales: Pite, Helena, Aguiar, Laura, Morello, Judit, Monteiro, Emília C, Alves, Ana Catarina, Bourbon, Mafalda, Morais-Almeida, Mário
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394599/
https://www.ncbi.nlm.nih.gov/pubmed/32801785
http://dx.doi.org/10.2147/JAA.S208823
_version_ 1783565251576332288
author Pite, Helena
Aguiar, Laura
Morello, Judit
Monteiro, Emília C
Alves, Ana Catarina
Bourbon, Mafalda
Morais-Almeida, Mário
author_facet Pite, Helena
Aguiar, Laura
Morello, Judit
Monteiro, Emília C
Alves, Ana Catarina
Bourbon, Mafalda
Morais-Almeida, Mário
author_sort Pite, Helena
collection PubMed
description The increasing knowledge of the mechanisms involved in metabolism is shifting the paradigms by which the pathophysiology of many pulmonary diseases is understood. Metabolic dysfunction is recognized in obesity-associated asthma, but other metabolic conditions have been shown to be independently related to asthma. Novel insights have also recently been brought by metabolomics in this filed. The purpose of this review is to discuss current perspectives regarding metabolic dysfunction in asthma, from obesity-related asthma to other metabolic conditions and the role of current pharmacological therapeutic strategies and lifestyle interventions. Obesity is a well-recognized risk factor for asthma across the lifespan, which is generally associated with poorer response to current available treatments, rendering a more severe, refractory disease status. Besides the epidemiological and clinical link, untargeted metabolomics studies have recently supported the obesity-associated asthma phenotype at the molecular level. Not only obesity-related, but also other aspects of metabolic dysregulation can be independently linked to asthma. These include hyperinsulinemia, dyslipidemia and hypertension, which need to be taken into account, even in the non-obese patient. Untargeted metabolomics studies have further highlighted several other metabolic pathways that can be altered in asthma, namely regarding oxidative stress and systemic inflammation, and also suggesting the importance of microbiota in asthma pathogenesis. Considering the reduced response to corticosteroids, other pharmacologic treatments have been shown to be effective regardless of body mass index. Non-pharmacologic treatments (namely weight reduction and dietary changes) may bring substantial benefit to the asthmatic patient. Taken together, this evidence points towards the need to improve our knowledge in this filed and, in particular, to address the influence of environmental factors in metabolic dysfunction and asthma development. Personalized medicine is definitely needed to optimize treatment, including a holistic view of the asthmatic patient in order to set accurate pharmacologic therapy together with dietary, physical exercise and lifestyle interventions.
format Online
Article
Text
id pubmed-7394599
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73945992020-08-13 Metabolic Dysfunction and Asthma: Current Perspectives Pite, Helena Aguiar, Laura Morello, Judit Monteiro, Emília C Alves, Ana Catarina Bourbon, Mafalda Morais-Almeida, Mário J Asthma Allergy Review The increasing knowledge of the mechanisms involved in metabolism is shifting the paradigms by which the pathophysiology of many pulmonary diseases is understood. Metabolic dysfunction is recognized in obesity-associated asthma, but other metabolic conditions have been shown to be independently related to asthma. Novel insights have also recently been brought by metabolomics in this filed. The purpose of this review is to discuss current perspectives regarding metabolic dysfunction in asthma, from obesity-related asthma to other metabolic conditions and the role of current pharmacological therapeutic strategies and lifestyle interventions. Obesity is a well-recognized risk factor for asthma across the lifespan, which is generally associated with poorer response to current available treatments, rendering a more severe, refractory disease status. Besides the epidemiological and clinical link, untargeted metabolomics studies have recently supported the obesity-associated asthma phenotype at the molecular level. Not only obesity-related, but also other aspects of metabolic dysregulation can be independently linked to asthma. These include hyperinsulinemia, dyslipidemia and hypertension, which need to be taken into account, even in the non-obese patient. Untargeted metabolomics studies have further highlighted several other metabolic pathways that can be altered in asthma, namely regarding oxidative stress and systemic inflammation, and also suggesting the importance of microbiota in asthma pathogenesis. Considering the reduced response to corticosteroids, other pharmacologic treatments have been shown to be effective regardless of body mass index. Non-pharmacologic treatments (namely weight reduction and dietary changes) may bring substantial benefit to the asthmatic patient. Taken together, this evidence points towards the need to improve our knowledge in this filed and, in particular, to address the influence of environmental factors in metabolic dysfunction and asthma development. Personalized medicine is definitely needed to optimize treatment, including a holistic view of the asthmatic patient in order to set accurate pharmacologic therapy together with dietary, physical exercise and lifestyle interventions. Dove 2020-07-27 /pmc/articles/PMC7394599/ /pubmed/32801785 http://dx.doi.org/10.2147/JAA.S208823 Text en © 2020 Pite et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Pite, Helena
Aguiar, Laura
Morello, Judit
Monteiro, Emília C
Alves, Ana Catarina
Bourbon, Mafalda
Morais-Almeida, Mário
Metabolic Dysfunction and Asthma: Current Perspectives
title Metabolic Dysfunction and Asthma: Current Perspectives
title_full Metabolic Dysfunction and Asthma: Current Perspectives
title_fullStr Metabolic Dysfunction and Asthma: Current Perspectives
title_full_unstemmed Metabolic Dysfunction and Asthma: Current Perspectives
title_short Metabolic Dysfunction and Asthma: Current Perspectives
title_sort metabolic dysfunction and asthma: current perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394599/
https://www.ncbi.nlm.nih.gov/pubmed/32801785
http://dx.doi.org/10.2147/JAA.S208823
work_keys_str_mv AT pitehelena metabolicdysfunctionandasthmacurrentperspectives
AT aguiarlaura metabolicdysfunctionandasthmacurrentperspectives
AT morellojudit metabolicdysfunctionandasthmacurrentperspectives
AT monteiroemiliac metabolicdysfunctionandasthmacurrentperspectives
AT alvesanacatarina metabolicdysfunctionandasthmacurrentperspectives
AT bourbonmafalda metabolicdysfunctionandasthmacurrentperspectives
AT moraisalmeidamario metabolicdysfunctionandasthmacurrentperspectives